Vishwa Patel

Employment

• BioDev Services Pvt. Ltd Sr. Reserach Associate
  2020 - 2022
• BioDev Services Pvt. Ltd Reserach Associate
  2020 - 2021

Education

• The University of Texas at Austin Doctorate in Pharmaceuticals Sciences
  2022 - Present
• L.M College of Pharmacy Master of Pharmacy
  2018 - 2020
• L.J Institude of Pharmacy
  2014 - 2018

Projects & Funding

Projects & funding information is unavailable.

Publications (8)

• The Lipid Switch: Ultra-High Dose Omega Fatty Acids Determine MYCN Neuroblastoma Fate Through Oxylipin Competition
  2025 DOI: 10.20944/preprints202510.1399.v1
  +Save
• Divergent Effects of Ultra-High Dose Arachidonic Acid versus Docosahexaenoic Acid on MYCN-Driven Neuroblastoma Progression in a Syngeneic Mouse Model
  2025 DOI: 10.1101/2025.05.06.652504
  +Save
• Ultra-High Dose Oral ω3 Eicosapentaenoic Acid (EPA), Docosahexaenoic Acid (DHA), or Oxidation-Resistant Deuterated DHA Block Tumorigenesis in a MYCN-Driven Neuroblastoma Model
  Cancers 2025 DOI: 10.3390/cancers17030362
  +Save
• Noncoding elements within MYCN mRNA are autonomous drivers of oncogenesis in neuroblastoma
  2025 DOI: 10.1101/2025.01.10.632492
  +Save
• Novel sex-biased outcomes in neuroblastoma are associated with distinct gene expression and chromosomal loss patterns
  2024 DOI: 10.1101/2024.06.14.599094
  +Save
• High dose ω3 eicosapentaenoic acid and docosahexaenoic acid block, whereas ω6 arachidonic acid accelerates,MYCN-driven tumorigenesisin vivo
  2024 DOI: 10.1101/2024.05.30.596731
  +Save
• Cellular cross talk between epicardial fat and cardiovascular risk
  Journal of Basic and Clinical Physiology and Pharmacology 2022 DOI: 10.1515/jbcpp-2022-0230
  +Save
• Chemokine Ligand 2 – Chemokines Receptor 2 As A Noval Drug Target
  Open Access Journal of Toxicology 2022 DOI: 10.19080/oajt.2022.05.555665
  +Save